Nowadays glaucoma is one of the leading causes of irreversible blindness worldwide. The main goal in preservation of vision in glaucoma patients is reducing intraocular pressure (IOP), which is considered the main controlled risk factor for progression of glaucomatous optic neuropathy. The article discusses the effectiveness and safety of various transscleral laser technologies in the treatment of glaucoma. Modern transscleral laser technologies that affect the uveoscleral drainage and scleral hydro-permeability are less traumatic and more gentle making them promising in the treatment of patients with early stages of glaucoma, and not only in terminal glaucoma with pain syndrome resistant to conventional treatment ("last resort surgery").
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/oftalma2020136061113 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Slow-Coagulation Transscleral Cyclophotocoagulation in Pseudoexfoliation Glaucoma.
J Glaucoma
January 2025
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Purpose: To evaluate the outcomes of slow-coagulation transscleral cyclophotocoagulation (SC-TSCPC) in pseudoexfoliation glaucoma (PXG).
Methods: A single-center, retrospective non-comparative study including consecutive patients with medically uncontrolled PXG who underwent SC-TSCPC (1250-milliwatt power and 4-second duration). The primary outcome measure was surgical success (defined as intraocular pressure (IOP) between 6 - 21 mmHg with ≥20% reduction compared to baseline and no need for further glaucoma surgeries or development of vision-threatening complications).
Outcomes of Ahmed Glaucoma Valve Implantation with Subsequent Trans-Scleral Diode Cyclophotocoagulation as the Main Intervention if IOP Remained Medically Uncontrolled.
Clin Ophthalmol
December 2024
Glaucoma Center of San Francisco, San Francisco, CA, USA.
Purpose: To evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) implantation with subsequent trans-scleral diode cyclophotocoagulation (CPC) as the main intervention if IOP remained medically uncontrolled.
Patients And Methods: Charts of 108 consecutive eyes (90 patients) that underwent AGV implantation from 2003 to 2018 at a single clinical practice were retrospectively reviewed. The procedure was considered a failure if any of the following occurred: additional incisional glaucoma surgery, IOP >21 mmHg or < 20% reduction from baseline on 2 consecutive study visits after 3 months, IOP ≤ 5 mmHg on 2 consecutive study visits after 3 months, loss of light perception, or AGV removal.
Long-Term Treatment Outcomes of Micropulse Transscleral Cyclophotocoagulation in Primary and Secondary Glaucoma: A 5-Year Analysis.
Ophthalmol Ther
December 2024
University Eye Clinic Maastricht, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
Introduction: To investigate 5-year outcomes on intraocular pressure (IOP) and safety of micropulse transscleral cyclophotocoagulation (TSCPC) in patients with glaucoma.
Methods: Patients with mild to advanced glaucoma who underwent a standardized micropulse TSCPC procedure at the University Eye Clinic Maastricht from November 2016 to February 2019 were included.
Results: A total of 165 eyes were included, with outcomes for 112 eyes available after 5-year follow-up.
[Application progress of micropulse wave transscleral laser treatment in glaucoma].
Zhonghua Yan Ke Za Zhi
December 2024
Aier Glaucoma Institute, Hunan Engineering Research Center for Glaucoma with Artificial Intelligence in Diagnosis and Application of New Materials, Changsha Aier Eye Hospital, Changsha410015, China.
Glaucoma is the leading cause of blindness worldwide, and reducing intraocular pressure is crucial to delaying its progression. This review aims to explore the application progress of micropulse wave transscleral laser treatment (mTLT) in the treatment of glaucoma. This article introduces the evolution of ciliary body destructive surgical methods, and focuses on the mechanism of mTLT in the treatment of glaucoma, including reducing aqueous humor production, increasing the uveoscleral pathway and trabecular meshwork pathway for aqueous humor outflow.
View Article and Find Full Text PDFMicroPulse Transscleral Laser Therapy: A Retrospective Study of Dose Efficacy and Safety.
J Curr Glaucoma Pract
October 2024
Department of Ophthalmology, Rutgers New Jersey Medical School, Newark, New Jersey, United States.
Aim: To evaluate the efficacy and safety of MicroPulse transscleral laser therapy (MPTLT) for cyclophotocoagulation in the treatment of glaucoma with different doses of energy.
Materials And Methods: A retrospective review was done of 136 eyes in 90 patients treated with MPTLT between 2018 and 2022. Intraocular pressures (IOP) at follow-ups were compared with a paired student -test and treatment outcomes with a Chi-squared test.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!